Lyrica (Pregabalin) Patent Expiration, LOE Window & CMS Spending

Lyrica (Pregabalin) by Viatris: Off-Patent Genericized (AB Competition), 23 AB generics, $126.9M 2024 CMS Part D & Medicaid spend, and 31 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorViatris
FDA Application & PathwayN021446 (NDA)
Exclusivity / Cliff HorizonOff-Patent Genericized (AB Competition)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity DateNot listed / N/A
Orange Book Patents (*PED Extensions)0 patents (0 *PED)
Active AB-Rated Generic Competitors23
2024 CMS Total Public Spend$126.9M
2024 Medicare Part D Spend$62.0M
2024 Medicaid Spend$64.9M
Reported Wholesale Price Change (CA SB 17)31 WAC filings (max 17.9% 2-yr change)

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Viatris across sibling Meru public-data platforms.